Sign in to view content

Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First Time 26-Week Interim Analysis Results from the Phase 2 LUNA Study

Charles C Wykoff, MD, PhD, FASRS

Video
Published 2024

Related

TIE2, VEGF, and Integrin Receptor Interplay and its Role in Retinal Disease
Peter K. Kaiser, MD FASRS
Updates from the Field
2020
Brolucizumab in HAWK/HARRIER: Outcomes, Efficacy, & Dosing Status – Everything You Need to Know!
David M. Brown, MD
Updates from the Field
2018
Intraoperative Use of Microscope-Integrated OCT for Subretinal Gene Therapy
Ninel Z. Gregori, MD
Annual Meeting Talks
2018

Category: AMD-Neovascular

See more